Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

Comments

Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer

Carlos L Arteaga email

Breast Cancer Res 2003, 5:96-100doi:10.1186/bcr574

No comments have yet been made on this article

Post a comment


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.